LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akcijų sąrašas・Gilead Sciences Inc.

Search

Gilead Sciences Inc.

Uždarymo kaina

SektoriusSveikatos priežiūra

136.29 2.2

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

133.11

Max

136.69

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-869M 2.2B
Pardavimai	156M 7.9B
P/E Sektoriaus vid.	19.428 49.8
Dividendų pajamingumas	2.4
Pelno marža	27.546
Darbuotojai	17,000
EBITDA	-2.3B 2.3B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+20.39% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.40% 2.25%
Kitas uždarbis	2026-05-07
Kitas dividendų mokėjimo data	2026-06-26
Kita Ex Dividend data	2026-06-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-24B 165B
Ankstesnė atidarymo kaina	134.09
Ankstesnė uždarymo kaina	136.29

Naujienos nuotaikos

By Acuity

25%

75%

65 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

97.33 / 103.17 Palaikymas ir pasipriešinimas

Gilead Sciences Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-07 14:24; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

2026-04-07 12:53; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

2026-04-01 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026-03-23 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026-03-23 22:55; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026-04-28 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

2026-04-17 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

2026-04-17 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

2026-04-07 14:36; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

2026-04-07 14:35; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

2026-04-07 14:34; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: Gilead Will Also Buy TUB-030

2026-04-07 14:28; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

2026-04-07 14:23; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Gilead Buying Another Cancer-Drug Partner -- Market Talk

2026-04-07 13:55; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

2026-04-07 13:14; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Tubulis Deal Includes $3.15B Upfront Cash Consideration on Cash-Free, Debt-Free Basis >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy German Clinical-Stage Biotech Tubulis for Up to $5 Billion >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead To Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate And Next Generation Platform To Further Strengthen Oncology Pipeline >GILD

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026-04-01 20:13; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026-03-24 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

2026-03-24 14:25; UTC

Įsigijimai, susijungimai, perėmimai

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

2026-03-24 13:35; UTC

Įsigijimai, susijungimai, perėmimai

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

2026-03-24 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. -- Barrons.com

2026-03-23 22:40; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026-03-23 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

Akcijų palyginimas

Kainos pokytis

Gilead Sciences Inc. Prognozė

Kainos tikslas

By TipRanks

20.39% į viršų

12 mėnesių prognozė

Vidutinis 159.74 USD 20.39%

Aukščiausias 180 USD

Žemiausias 123 USD

Remiantis 23 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gilead Sciences Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

23 ratings

18

Pirkti

5

Laikyti

0

Parduoti

Remiantis 23 analitikų, pateikusių Gilead Sciences Inc. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

97.33 / 103.17Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Rinkos nuotaikos

By Acuity

65 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Kitos sektoriaus akcijos

LLY

Eli Lilly and Co.

986

JNJ

Johnson and Johnson

224.47

ABBV

AbbVie Inc

204.99

UNH

UnitedHealth Group Inc

366.96

AZN

AstraZeneca PLC

184.44

Live chat